INTRODUCTION: Endoscopic mucosal resection (EMR) and ablation technologies have markedly changed the treatment of early esophageal neoplasia. We analyzed treatment and outcomes of patients undergoing multimodal endoscopic treatment of early esophageal neoplasia at our institution. METHODS: Records of patients undergoing endoscopic treatment for esophageal low-grade intraepithelial neoplasia (LGIN, n = 11), high-grade intraepithelial neoplasia (HGIN, n = 24), or T1N0M0 neoplasia (n = 10), presenting between 2007 and 2009, were reviewed. Outcomes included eradication of neoplasia/intestinal metaplasia, development of metachronous neoplasia, and progression to surgical resection. RESULTS: There were 45 patients, 96% male, with a mean age 67 years. The degree of neoplasia prior to intervention was intramucosal (8) or submucosal (2) carcinoma in 10, HGIN in 24, and LGIN in 11. Patients underwent a total of 166 procedures (median 3/patient, range 1-9). These included 120 radiofrequency ablation sessions, 38 EMRs, and 8 cryoablations. Mean follow-up was 21.3 months. Neoplasia and intestinal metaplasia were eradicated in 87.2% and 56.4% of patients, respectively, while 15.4% developed metachronous neoplasia. Three patients underwent esophagectomy. No patient developed unresectable disease or died. CONCLUSION: Endoscopic treatment of early esophageal neoplasia is safe and effective in the short term. A minority of treated patients developed recurrent neoplasia, which is usually amenable to further endoscopic therapy. Complications are relatively minor and uncommon. Endoscopic therapy as the initial treatment for early esophageal neoplasia is an emerging standard of care.
INTRODUCTION: Endoscopic mucosal resection (EMR) and ablation technologies have markedly changed the treatment of early esophageal neoplasia. We analyzed treatment and outcomes of patients undergoing multimodal endoscopic treatment of early esophageal neoplasia at our institution. METHODS: Records of patients undergoing endoscopic treatment for esophageal low-grade intraepithelial neoplasia (LGIN, n = 11), high-grade intraepithelial neoplasia (HGIN, n = 24), or T1N0M0 neoplasia (n = 10), presenting between 2007 and 2009, were reviewed. Outcomes included eradication of neoplasia/intestinal metaplasia, development of metachronous neoplasia, and progression to surgical resection. RESULTS: There were 45 patients, 96% male, with a mean age 67 years. The degree of neoplasia prior to intervention was intramucosal (8) or submucosal (2) carcinoma in 10, HGIN in 24, and LGIN in 11. Patients underwent a total of 166 procedures (median 3/patient, range 1-9). These included 120 radiofrequency ablation sessions, 38 EMRs, and 8 cryoablations. Mean follow-up was 21.3 months. Neoplasia and intestinal metaplasia were eradicated in 87.2% and 56.4% of patients, respectively, while 15.4% developed metachronous neoplasia. Three patients underwent esophagectomy. No patient developed unresectable disease or died. CONCLUSION: Endoscopic treatment of early esophageal neoplasia is safe and effective in the short term. A minority of treated patients developed recurrent neoplasia, which is usually amenable to further endoscopic therapy. Complications are relatively minor and uncommon. Endoscopic therapy as the initial treatment for early esophageal neoplasia is an emerging standard of care.
Authors: Nicholas J Shaheen; Bruce D Greenwald; Anne F Peery; John A Dumot; Norman S Nishioka; Herbert C Wolfsen; J Steven Burdick; Julian A Abrams; Kenneth K Wang; Damien Mallat; Mark H Johnston; Alvin M Zfass; Jenny O Smith; James S Barthel; Charles J Lightdale Journal: Gastrointest Endosc Date: 2010-04 Impact factor: 9.427
Authors: Wouter L Curvers; Fiebo J ten Kate; Kausilia K Krishnadath; Mike Visser; Brenda Elzer; Lubertus C Baak; Clarisse Bohmer; Rosalie C Mallant-Hent; Arnout van Oijen; Anton H Naber; Pieter Scholten; Olivier R Busch; Harriët G T Blaauwgeers; Gerrit A Meijer; Jacques J G H M Bergman Journal: Am J Gastroenterol Date: 2010-05-11 Impact factor: 10.864
Authors: Virender K Sharma; H Jae Kim; Ananya Das; Christopher D Wells; Cuong C Nguyen; David E Fleischer Journal: Am J Gastroenterol Date: 2009-01-27 Impact factor: 10.864
Authors: Jennifer Chennat; Vani J A Konda; Andrew S Ross; Alberto Herreros de Tejada; Amy Noffsinger; John Hart; Shang Lin; Mark K Ferguson; Mitchell C Posner; Irving Waxman Journal: Am J Gastroenterol Date: 2009-08-18 Impact factor: 10.864
Authors: Roos E Pouw; Joep J Gondrie; Carine M Sondermeijer; Fiebo J ten Kate; Thomas M van Gulik; Kausilia K Krishnadath; Paul Fockens; Bas L Weusten; Jacques J Bergman Journal: J Gastrointest Surg Date: 2008-08-13 Impact factor: 3.452
Authors: Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale Journal: N Engl J Med Date: 2009-05-28 Impact factor: 91.245
Authors: Valerie A Williams; Thomas J Watson; Fernando A Herbella; Oliver Gellersen; Daniel Raymond; Carolyn Jones; Jeffrey H Peters Journal: J Gastrointest Surg Date: 2007-10-02 Impact factor: 3.452
Authors: Ganapathy A Prasad; Tsung Teh Wu; Dennis A Wigle; Navtej S Buttar; Louis-Michel Wongkeesong; Kelly T Dunagan; Lori S Lutzke; Lynn S Borkenhagen; Kenneth K Wang Journal: Gastroenterology Date: 2009-06-12 Impact factor: 22.682
Authors: Mark F Berry; Josiane Zeyer-Brunner; Anthony W Castleberry; Jeremiah T Martin; Beat Gloor; Ricardo Pietrobon; Thomas A D'Amico; Mathias Worni Journal: J Thorac Oncol Date: 2013-06 Impact factor: 15.609
Authors: Lauren J Taylor; Caprice C Greenberg; Anne O Lidor; Glen E Leverson; James D Maloney; Ryan A Macke Journal: Cancer Date: 2016-09-28 Impact factor: 6.860